Eculizumab biosimilar (CinnaGen)

依库丽单抗生物类似药(CinnaGen)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameEculizumab biosimilar (CinnaGen)
Drug Alias Name依库丽单抗生物仿制药(CinnaGen)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionComplement C5 inhibitors
TargetsComplement C5
Therapy Area/IndicationsHemoglobinuria, Paroxysmal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCinnagen
China Registration ClassN/A

Develop Information

Active CompaniesCinnagen
Inactive CompaniesN/A
Active IndicationsHemoglobinuria, Paroxysmal
Inactive IndicationsN/A

Other Information

ATC CodeL04AJ01
Related LinksN/A